Related Experiment Videos
Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases.
M Fukagawa1, J J Kazama, T Shigematsu
1Division of Nephrology and Dialysis Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. fukagawa@med.kobe-u.ac.jp
Summary
In uremia, skeletal resistance to parathyroid hormone (PTH) leads to relative hypoparathyroidism, requiring higher PTH levels for normal bone turnover. Further research is needed to understand and treat this condition.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Skeletal resistance to parathyroid hormone (PTH) was a proposed mechanism for PTH hypersecretion in uremia.
- Therapeutic advancements have revealed this as relative hypoparathyroidism concerning bone turnover.
- Elevated PTH levels (2-3x normal) are needed to maintain normal bone turnover in uremia.
Purpose of the Study:
- To investigate the role of skeletal resistance to PTH in uremia.
- To understand the implications of relative hypoparathyroidism on bone turnover.
- To identify potential therapeutic targets for uremic bone abnormalities.
Main Methods:
- Review of recent studies on PTH assays and bone turnover in uremia.
- Analysis of the impact of therapeutic modalities on PTH levels.
- Exploration of cellular and molecular mechanisms of osteoclastogenesis in uremia.
Main Results:
- Conventional intact PTH assays may overestimate PTH activity.
- Several steps in osteoclastogenesis appear disrupted in uremic conditions.
- Relative hypoparathyroidism is now recognized as a key feature in uremic bone disease.
Conclusions:
- Skeletal resistance to PTH contributes to relative hypoparathyroidism in uremia.
- Further cellular and molecular studies are essential.
- Developing preventive and therapeutic strategies requires a deeper understanding of these abnormalities.